ATOS Atossa Therapeutics Inc

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Details of the company's participation are as follows:

• Cantor Fitzgerald Global Healthcare Conference 2023
• Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.
• Date and Time: Thursday, September 28th at 9:10 A.M. ET
• Location: New York, NY

Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.

About Atossa TherapeuticsAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:Eric Van ZantenVP, Investor and Public Relations610-529-6219eric.vanzanten@atossainc.com